Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company’s novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. T...

ENCINITAS, CALIF., November 4, 2023 – Kiora Pharmaceuticals (NASDAQ: KPRX) today announced topline results of a Phase I/II clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class small molecule, has the potential to meaningfully improve vision ...

In early August 2023, Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced a sharpened clinical development focus on rare retinal diseases with large unmet needs, initially dedicating attention to inherited retinal diseases (IRDs). Kiora recently completed a Phase 1b study of ...